Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Sarepta
Biotech
With Sarepta in its sights, PepGen prices IPO to fund DMD trials
PepGen missed the bottom end of its IPO range but upped the share count, enabling it to reel in $108 million to challenge Sarepta.
Nick Paul Taylor
May 6, 2022 8:50am
Editas brings on Sarepta CMO—for CEO swap, not empty CMO role
Apr 14, 2022 10:35am
Sarepta, with pivotal data in sight, dumps Lysogene gene therapy
Jan 13, 2022 8:35am
Pfizer halts Duchenne gene therapy trial after patient death
Dec 21, 2021 9:30am
PepGen raises $113M to challenge Sarepta in DMD
Aug 5, 2021 7:00am
Roche to pay Sarepta $1B upfront for DMD gene therapy rights
Dec 23, 2019 4:19am
